Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 7/20 | 0.46 |
| ▸ | BCHE | P06276 | 4/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.44 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.41 |
| ▸ | YAP1 | P46937 | 1/20 | 0.41 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1467954 | 0.95 | CCNT1 (0.47) | HTR6CCNT1HDAC1TP53YAP1 | |
| SCHEMBL1466903 | 0.87 | CCNT1 (0.48) | CCNT1USP30TP53PARP1 | |
| SCHEMBL1467928 | 0.85 | CCNT1 (0.51) | CCNT1USP30TP53 | |
| SCHEMBL1469668 | 0.85 | FAAH (0.46) | CCNT1USP30HDAC1YAP1 | |
| SCHEMBL1467663 | 0.84 | USP30 (0.51) | HTR6BCHECCNT1ACKR3USP30 | |
| SCHEMBL1468041 | 0.84 | SLC2A1 (0.44) | CCNT1CDK9ACKR3USP30 | |
| SCHEMBL1468032 | 0.84 | CCNT1 (0.43) | CCNT1USP30TP53 | |
| SCHEMBL1468334 | 0.81 | USP30 (0.43) | CCNT1USP30METTL3 | |
| SCHEMBL1467766 | 0.80 | PRMT5 (0.43) | CCNT1USP30METTL3 | |
| SCHEMBL1467462 | 0.80 | JAK2 (0.43) | CCNT1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268822-B2 | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20110071134-A1 | 2-(AMINO-SUBSTITUTED)-4-ARYL PYRIMIDINES AND RELATED COMPOUNDS USEFUL FOR TREATING INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-7732444-B2 | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| EP-2123647-A1 | 2-(amino-substituted)-4-phenyl pyrimidines useful for treating inflammatory diseases | Millennium Pharmaceuticals, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| EP-1701944-B1 | 2-(AMINO-SUBSTITUTED)-4-ARYL PYRAMIDINES AND RELATED COMPOUNDS USEFUL FOR TREATING INFLAMMATORY DISEASES | MILLENNIUM PHARM INC (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-1701944-A2 | 2-(AMINO-SUBSTITUTED)-4-ARYL PYRAMIDINES AND RELATED COMPOUNDS USEFUL FOR TREATING INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-09-20 | — | — | EP | disclosed |
| US-20060040968-A1 | 2-(Amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2006-02-23 | — | — | US | disclosed |
| WO-2005066139-A2 | 2-(AMINO-SUBSTITUTED)-4-ARYL PYRAMIDINES AND RELATED COMPOUNDS USEFUL FOR TREATING INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071134-A1 | 2-(AMINO-SUBSTITUTED)-4-ARYL PYRIMIDINES AND RELATED COMPOUNDS USEFUL FOR TREATING INFLAMMATORY DISEASES | PRKCZ, PRKCQ, PRKCE | HTR6 2911/4885BCHE 1555/4885CCNT1 2855/4885 |
| US-20060040968-A1 | 2-(Amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases | PRKCZ, PRKCQ, PRKCE | HTR6 2911/4885BCHE 1555/4885CCNT1 2855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.